Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Clements

Showing results (431-440 of 462) with videos related to

Pageof 47
Sort By:
Macromolecular Bioscience|October 11, 2014
Biocompatible, biodegradable and porous liquid crystal elastomer scaffolds for spatial cell culturesAnshul Sharma, Abdollah Neshat, Cory J Mahnen, et al.
Arthritis and Rheumatism|June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trialP J Clements, D E Furst, W K Wong, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of Internal Medicine|April 15, 1993
Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis)K J Bulpitt, P J Clements, P A Lachenbruch, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Journal of Applied Toxicology : JAT|December 21, 2016
Genotoxic risk of ethyl-paraben could be related to telomere shorteningF Finot, A Kaddour, L Morat, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Pageof 47

Showing results (431-440 of 462) with videos related to

Sort By:
Pageof 47
Macromolecular Bioscience|October 11, 2014
Biocompatible, biodegradable and porous liquid crystal elastomer scaffolds for spatial cell culturesAnshul Sharma, Abdollah Neshat, Cory J Mahnen, et al.
Arthritis and Rheumatism|June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trialP J Clements, D E Furst, W K Wong, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of Internal Medicine|April 15, 1993
Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis)K J Bulpitt, P J Clements, P A Lachenbruch, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Journal of Applied Toxicology : JAT|December 21, 2016
Genotoxic risk of ethyl-paraben could be related to telomere shorteningF Finot, A Kaddour, L Morat, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Pageof 47